Jacobs Levy Equity Management Inc. Sells 262,010 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN)

Jacobs Levy Equity Management Inc. lessened its position in Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 93.5% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 18,261 shares of the company's stock after selling 262,010 shares during the period. Jacobs Levy Equity Management Inc.'s holdings in Design Therapeutics were worth $113,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in DSGN. Invesco Ltd. acquired a new stake in Design Therapeutics in the fourth quarter valued at approximately $71,000. China Universal Asset Management Co. Ltd. acquired a new stake in Design Therapeutics in the fourth quarter valued at approximately $74,000. Kennedy Capital Management LLC acquired a new stake in Design Therapeutics in the fourth quarter valued at approximately $88,000. Intech Investment Management LLC purchased a new position in shares of Design Therapeutics during the fourth quarter valued at approximately $109,000. Finally, Wells Fargo & Company MN boosted its position in shares of Design Therapeutics by 27.8% during the fourth quarter. Wells Fargo & Company MN now owns 18,428 shares of the company's stock valued at $114,000 after buying an additional 4,013 shares during the last quarter. Institutional investors and hedge funds own 56.64% of the company's stock.

Design Therapeutics Trading Down 1.6%

Shares of NASDAQ:DSGN traded down $0.06 during mid-day trading on Friday, hitting $3.81. 184,751 shares of the company traded hands, compared to its average volume of 186,308. The stock has a market cap of $216.29 million, a P/E ratio of -4.48 and a beta of 1.77. Design Therapeutics, Inc. has a 12-month low of $2.60 and a 12-month high of $7.77. The stock has a 50-day moving average price of $3.77 and a two-hundred day moving average price of $4.82.

Design Therapeutics (NASDAQ:DSGN - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.03). As a group, analysts expect that Design Therapeutics, Inc. will post -0.91 earnings per share for the current year.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.